Renaissance Technologies’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
Other funds holding TSHA
ACA
RCM
VPC
RI
Renaissance Technologies's TSHA Position: Q2 2026 in Review
Renaissance Technologies sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 413,203 shares — an estimated $1.85M sold.
Renaissance Technologies first reported a position in TSHA in Q1 2022 and held it in 14 quarters. The position peaked at $1.95M in Q2 2022. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.
- Renaissance Technologies reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
- Renaissance Technologies sold 413,203 Taysha Gene Therapies shares in Q2 2026, an estimated $1.85M.
- Renaissance Technologies first reported a position in Taysha Gene Therapies in Q1 2022 and held it in 14 quarters.
- Renaissance Technologies's Taysha Gene Therapies position peaked at $1.95M in Q2 2022.
- 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.